Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gelesis

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

The latest from pharma, biotech and healthcare

- PMLiVE

GSK sells eczema and psoriasis drug to Dermavant for £250m

The British group is selling off assets outside core therapy areas to boost R&D

- PMLiVE

Weekly industry appointments

GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board

- PMLiVE

GSK’s vaccines president Debruyne heads for the exit

Roger Connor to take on the role in latest shake up

- PMLiVE

Kevin Sin joins GSK

He becomes senior VP, head of worldwide business development

AstraZeneca AZ

PMCPA takes AZ to task over asthma drug press release

Concluded that the data in the release had not been “placed in context”

- PMLiVE

Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

- PMLiVE

GSK gets maintenance indication for Trelegy

Will now treat airflow obstruction in COPD patients

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links